Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
Nippon Boehringer Ingelheim’s pharma revenue marked the fifth consecutive year of growth in 2023, rising 7% over the prior year as the mainstays Ofev (nintedanib) and Jardiance (empagliflozin) continued to deliver brisk performances, the company said on May 28. In…
To read the full story
Related Article
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
- Jardiance, Ofev Continue to Drive Boehringer’s Global Sales
April 17, 2024
- Nippon BI Logs 4% Growth on NHI Price-Based Sales; Jardiance, Ofev as Engines
April 21, 2023
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
BUSINESS
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
- Meiji Pharma Wins Defamation Suit over Kostaive Remarks
November 2, 2026
- Senju Licenses Late-Stage CRAO Drug to Kiora in Ex-Asia Deal
November 2, 2026
- Towa Pushes Back Tanabe Factory Buyout by One Month
November 2, 2026
- Fatal Drug Mix-Up Prompts Safety Alert on Two Amphotericin B Products
November 2, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…